Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Ying-Wei Li"'
Autor:
Dai Cao, Die Chen, Jiang-Nan Xia, Wen-Yan Wang, Guo-Yuan Zhu, Li-Wen Chen, Chuantao Zhang, Bo Tan, Hui Li, Ying-Wei Li
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 155, Iss , Pp 113705- (2022)
Lung cancer is the leading cause of cancer-related death worldwide. The development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) has brought favorable survival benefits to patients
Externí odkaz:
https://doaj.org/article/13c6906933c846ea9c6ac806ba133309
Autor:
Dai Cao, Guo-Yuan Zhu, Yan Lu, Aiping Yang, Die Chen, Hui-Jie Huang, Shu-Xian Peng, Li-Wen Chen, Ying-Wei Li
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 129, Iss , Pp 110462- (2020)
Triple-negative breast cancer (TNBC) is a highly lethal subtype of breast cancer associated with early relapse and metastasis. Epithelial to mesenchymal transition (EMT) plays pivotal roles in the progression of TNBC, including inducing cancer stem c
Externí odkaz:
https://doaj.org/article/d3e1772cdbde4d999f06376fd2994945
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 115, Iss , Pp - (2019)
EGFR tyrosine kinase inhibitors (EGFR-TKIs) improve the progression-free survival of patients with non-small cell lung cancer (NSCLC). However, most patients inevitably developed drug resistance. EGFR T790 M mutation is the major mechanism for resist
Externí odkaz:
https://doaj.org/article/1a1bd172479c4e279214dabaf816c65e
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e36891 (2012)
The cis-acting promoter element responsible for epigenetic silencing of retinoic acid receptor responder 1 (RARRES1) by methylation is unclear. Likewise, how aberrant methylation interplays effectors and thus affects breast neoplastic features remain
Externí odkaz:
https://doaj.org/article/6264257b7fd64263bcbaf7c93717c0cb
Publikováno v:
Rock Mechanics and Rock Engineering. 56:1585-1594
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f9bd7c47ec8e181f8e5612a485b6fb5
https://doi.org/10.1007/s00603-022-03109-x
https://doi.org/10.1007/s00603-022-03109-x
Publikováno v:
International Journal of Mechanical Sciences. 247:108171
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96400af6120dbf679091d5a06376c6c3
https://doi.org/10.1016/j.ijmecsci.2023.108171
https://doi.org/10.1016/j.ijmecsci.2023.108171
Autor:
Ying-Wei Li, Aiping Yang, Shu-Xian Peng, Hui-Jie Huang, Dai Cao, Guo-Yuan Zhu, Yan Lu, Li-Wen Chen, Die Chen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 129, Iss, Pp 110462-(2020)
Triple-negative breast cancer (TNBC) is a highly lethal subtype of breast cancer associated with early relapse and metastasis. Epithelial to mesenchymal transition (EMT) plays pivotal roles in the progression of TNBC, including inducing cancer stem c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a23172cfdcc7ff19b04429a348208d1
http://www.sciencedirect.com/science/article/pii/S0753332220306557
http://www.sciencedirect.com/science/article/pii/S0753332220306557
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 115, Iss, Pp-(2019)
EGFR tyrosine kinase inhibitors (EGFR-TKIs) improve the progression-free survival of patients with non-small cell lung cancer (NSCLC). However, most patients inevitably developed drug resistance. EGFR T790 M mutation is the major mechanism for resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4161e578276391c4500a715c98273801
http://www.sciencedirect.com/science/article/pii/S0753332219300186
http://www.sciencedirect.com/science/article/pii/S0753332219300186
Publikováno v:
Biomedicinepharmacotherapy = Biomedecinepharmacotherapie. 115
EGFR tyrosine kinase inhibitors (EGFR-TKIs) improve the progression-free survival of patients with non-small cell lung cancer (NSCLC). However, most patients inevitably developed drug resistance. EGFR T790 M mutation is the major mechanism for resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::64112acf0f8eabb9936668ca887ec7be
https://pubmed.ncbi.nlm.nih.gov/31055235
https://pubmed.ncbi.nlm.nih.gov/31055235
Autor:
Ashley L. Mussell, Jun Qu, Jun Li, Nuo Yang, Jianmin Zhang, Kayla E. Wilson, Jin Guo, He Shen, Amjad Farooq, Marius Sudol, Costa Frangou, Yinglong Zhang, Ying-Wei Li
Publikováno v:
Cell Cycle. 15:2497-2505
The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell fate and tumorigenesis. The pivotal effector of this pathway is YAP1, a transcriptional co-activator amplified in mouse and human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1befc758fbe7bcec5a37a09b04584c98
https://doi.org/10.1080/15384101.2016.1207836
https://doi.org/10.1080/15384101.2016.1207836